Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07819435
Recruiting Phase 2/3

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

NCT07819435 · tracked via the Priya Life Science USA tracker
Sponsor
Pelage Pharmaceuticals, Inc
Phase
Phase 2/3
Started
2026-09-21
Last updated
2026-10-02

Condition(s) studied

Androgenetic Alopecia

Investigational drug(s) / intervention(s)

PP405 0.05% Topical GelVehicle Topical Gel

PP405 0.05% Topical Gel: Medicated topical gel containing PP405 0.05%

Vehicle Topical Gel: Topical gel

Study summary

The study is designed to validate efficacy and long term safety of PP405.

Eligibility

Sex
MALE
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: 1. Males (assigned at birth) aged 18 to 55 years, inclusive at time of consent. 2. Able and willing to provide written informed consent 3. Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening. 4. Have a modified Norwood-Hamilton score of Type IV or Type V 5. Agree to comply with protocol procedures Exclusion Criteria: 1. Concomitant diagnosis of non-AGA forms of alopecia. 2. Use of other hair loss treatments within periods specified in protocol. 3. Use of excluded medications and procedures as specified in protocol. 4. Diagnosis of other medical conditions as specified in protocol. 5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.

Primary outcome measure(s)

Trial sites (17)

FacilityCityRegionStatus
Johnson Dermatology Fort Smith Arkansas Recruiting
Burke Pharmaceutical Research Hot Springs Arkansas Recruiting
Ablon Skin Institute and Research Center Manhattan Beach California Recruiting
Clinical Trials Research Institute Thousand Oaks California Recruiting
Skin Research Institute, LLC Coral Gables Florida Recruiting
MOORE Clinical Research, Inc. Tampa Florida Enrolling By Invitation
DelRicht Research (Experience Dermatology) Atlanta Georgia Recruiting
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana Recruiting
Indiana Clinical Trials Center Plainfield Indiana Recruiting
DelRicht Research @LA Dermatology Associates Baton Rouge Louisiana Recruiting
Minnesota Clinical Study Center New Brighton Minnesota Recruiting
DelRicht Research (Town Center Dermatology) Wildwood Missouri Recruiting
Dermatology and Laser Surgery Center Houston Texas Recruiting
Texas Dermatology & Laser Specialists San Antonio Texas Recruiting
Jordan Valley Dermatology Center South Jordan Utah Recruiting
Eurofins CRL Cosmetic LLC Forest Virginia Recruiting
Innovaderm Research Inc Montreal Quebec Recruiting

Other trials for the same condition

Safety and Efficacy of VDPHL01 in Males and Females With AGA Active, not recruiting
XVIE to Treat Androgenetic Alopecia (AGA) Starting soon
Efficacy and Safety of VDPHL01 in Males With AGA Active, not recruiting
Safety and Efficacy of VDPHL01 in Males With AGA Active, not recruiting
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07819435 on ClinicalTrials.gov ↗ ← All trials in the USA